Galectin Therapeutics Reports 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 03/29/24
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical DevelopmentGlobeNewsWire • 03/12/24
PureTech Presents Data from Phase 1 Trial of LYT-200 Targeting Galectin-9 in Solid Tumors at the ESMO Immuno-Oncology Congress 2023Business Wire • 12/07/23
UPDATE – Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateGlobeNewsWire • 11/13/23
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business UpdateGlobeNewsWire • 11/13/23
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLDGlobeNewsWire • 11/03/23
Galectin Therapeutics to Participate in the H.C. Wainwright 7th Annual NASH Investor Conference on October 24, 2023GlobeNewsWire • 10/23/23
Galectin Therapeutics Announces Nomination of Dr. Benjamin S. Carson, Sr. to Board of DirectorsGlobeNewsWire • 10/12/23
Galectin Therapeutics to Present Update on its Belapectin Liver Cirrhosis Program at the 20th Edition of Discovery on Target meeting, in Boston, September 25-28, 2023GlobeNewsWire • 09/26/23
Galectin Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference on September 13, 2023GlobeNewsWire • 09/13/23
Galectin Therapeutics Inc. (GALT)'s Technical Outlook is Bright After Key Golden CrossZacks Investment Research • 09/11/23
Galectin Therapeutics to Present Data on Liver Cirrhosis at the 9th Edition of the Paris NASH meeting, at Institut Pasteur, September 7th & 8th 2023GlobeNewsWire • 09/07/23
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business UpdateGlobeNewsWire • 08/14/23
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business UpdateGlobeNewsWire • 05/15/23
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023GlobeNewsWire • 04/27/23
Galectin Therapeutics' Statement Following the Recent 2023 Emerging Topic Conference on NASH Cirrhosis, Sponsored by the American Association for the Study of Liver DiseasesGlobeNewsWire • 04/18/23
Galectin Therapeutics Reports 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 03/30/23
Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic SteatohepatitisGlobeNewsWire • 03/16/23
Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology JournalGlobeNewsWire • 01/24/23
Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic SteatohepatitisGlobeNewsWire • 01/05/23